We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+19.83%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$24.2M
AUM Growth
+$4.43M
Cap. Flow
+$724K
Cap. Flow %
3%
Top 10 Hldgs %
99.75%
Holding
13
New
1
Increased
3
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$552K
2
BCAX
Bicara Therapeutics
BCAX
+$279K
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$55.7K
4
DFTX
Definium Therapeutics
DFTX
+$25.7K

Top Sells

Rank Stock Value
1
MTEM
Molecular Templates, Inc.
MTEM
+$157K
2
ABVX
Abivax
ABVX
+$30.4K

Sector Composition

Rank Sector Weight
1 Healthcare 91%
2 Financials 2.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XERS icon
1
Xeris Biopharma Holdings
XERS
$1.5B
$14.6M 60.31%
5,113,348
– –
RZLT icon
2
Rezolute
RZLT
$421M
$6.4M 26.47%
1,318,967
– –
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$1.64M 6.81%
2,867
+998
+53% +$552K
BRK.B icon
4
Berkshire Hathaway Class B
BRK.B
$1.06T
$530K 2.19%
1,151
+126
+12% +$55.7K
BCAX
5
Bicara Therapeutics
BCAX
$1.81B
$279K 1.15%
+10,941
New +$279K
DFTX
6
Definium Therapeutics
DFTX
$5.85B
$194K 0.8%
34,073
+3,690
+12% +$25.7K
LXEO icon
7
Lexeo Therapeutics
LXEO
$358M
$161K 0.67%
17,851
– –
ABVX
8
Abivax
ABVX
$12B
$131K 0.54%
11,365
-2,535
-18% -$30.4K
KYTX icon
9
Kyverna Therapeutics
KYTX
$452M
$112K 0.47%
22,981
– –
CMPX icon
10
Compass Therapeutics
CMPX
$378M
$80K 0.33%
43,465
– –
CNTX icon
11
Context Therapeutics
CNTX
$56.5M
$36.1K 0.15%
18,403
– –
ACET icon
12
Adicet Bio
ACET
$76.8M
$25.2K 0.1%
1,093
– –
MTEM
13
DELISTED
Molecular Templates, Inc.
MTEM
– –
-136,866
Closed -$157K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2024 Portfolio in Review

As of Q3 2024, Caxton Corporation held 13 positions worth $24.2M, up 22% from $19.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation's Q3 2024 filing shows 1 new, 3 increased, 1 reduced and 1 closed positions. Its largest new stake was Bicara Therapeutics: 10,941 shares worth $279K. The largest sale was Molecular Templates, Inc., an estimated $157K.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • Caxton Corporation's largest Q3 2024 buy was Bicara Therapeutics: 10,941 shares worth $279K.
  • Caxton Corporation added most to State Street SPDR S&P 500 ETF Trust in Q3 2024, an estimated $552K increase.
  • Caxton Corporation's biggest Q3 2024 reduction was Abivax, cutting an estimated $30.4K.
  • Caxton Corporation fully exited Molecular Templates, Inc. in Q3 2024, selling an estimated $157K.
  • Caxton Corporation's ten largest holdings make up 100% of its $24.2M portfolio in Q3 2024.
  • Caxton Corporation opened 1 new position and closed 1 in Q3 2024.
  • Caxton Corporation's portfolio value rose 22% quarter-over-quarter to $24.2M.

Based on Caxton Corporation's 13F filing for Q3 2024, filed 14 Nov 2024.